An up­start in the poly­clon­al an­ti­body biz just lined up $50M for its plan to dis­rupt a multi­bil­lion-dol­lar busi­ness

The multi­bil­lion-dol­lar busi­ness for im­muno­glo­bin prod­ucts is dom­i­nat­ed by three key play­ers: CSL, Shire and Gri­fols.  And one of them re­cent­ly in­vest­ed $50 mil­lion in a South San Fran­cis­co-based biotech that thinks it has a key to dis­rupt­ing the en­tire glob­al mar­ket.

The com­pa­ny is a lit­tle known pri­vate play­er called Gi­ga­Gen. It has all of 10 staffers who are now so close­ly packed in­to their work space that the com­pa­ny will have to find new digs to ex­pand in­to. But it has glob­al am­bi­tions to do some­thing com­plete­ly new in poly­clon­al an­ti­bod­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.